Core Insights - Hims & Hers (HIMS) is expanding its Weight Loss Program to the United Kingdom, launching the Hers platform to provide holistic weight management care to eligible women [1][7] Expansion and Growth - The weight-loss programs in the United States have been a significant growth driver for Hims & Hers in 2025, leading to rapid subscriber and revenue growth, supported by strong clinical outcomes and adherence metrics [2] - Following the success in the U.S., the company is focusing on international expansion, having already launched in Canada earlier this year and acquired the European telehealth platform Zava, which provides access to markets in Germany, France, and Ireland [2] Market Potential - The international expansion into the U.K. is part of a broader strategy to tap into lucrative markets, with 64% of adults in the U.K. classified as overweight or living with obesity, indicating a substantial target patient population [4] - Despite the high prevalence of obesity, access to advanced obesity treatments, such as GLP-1 drugs, remains limited in the U.K., creating an opportunity for Hims & Hers to provide seamless access to its Weight Loss Program [5] Service Offerings - The Hers platform will offer eligible customers transparent pricing and personalized weight management programs, guided by GMC-registered doctors after a thorough intake assessment [8] - The platform will include treatment options like branded GLP-1 drugs (e.g., Mounjaro, Wegovy) and non-prescription treatments (e.g., Orlos), along with comprehensive support including 24/7 care team access and resources for improving nutrition, movement, and sleep habits [9]